271 related articles for article (PubMed ID: 30480428)
21. Muscarinic acetylcholine M
Liu L; Huang Y; Huang Q; Zhao Z; Yu J; Wang L
Neuropharmacology; 2017 May; 117():376-386. PubMed ID: 28257887
[TBL] [Abstract][Full Text] [Related]
22. Long-term changes in the muscarinic M1 receptor induced by instantaneous formation of wash-resistant xanomeline-receptor complex.
De Lorme KC; Grant MK; Noetzel MJ; Polson SB; El-Fakahany EE
J Pharmacol Exp Ther; 2007 Dec; 323(3):868-76. PubMed ID: 17855477
[TBL] [Abstract][Full Text] [Related]
23. Discovery and Development of Muscarinic Acetylcholine M
Takai K; Enomoto T
Chem Pharm Bull (Tokyo); 2018; 66(1):37-44. PubMed ID: 29311510
[TBL] [Abstract][Full Text] [Related]
24. Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice.
Zhang W; Basile AS; Gomeza J; Volpicelli LA; Levey AI; Wess J
J Neurosci; 2002 Mar; 22(5):1709-17. PubMed ID: 11880500
[TBL] [Abstract][Full Text] [Related]
25. Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects.
Bymaster FP; Carter PA; Peters SC; Zhang W; Ward JS; Mitch CH; Calligaro DO; Whitesitt CA; DeLapp N; Shannon HE; Rimvall K; Jeppesen L; Sheardown MJ; Fink-Jensen A; Sauerberg P
Brain Res; 1998 Jun; 795(1-2):179-90. PubMed ID: 9622623
[TBL] [Abstract][Full Text] [Related]
26. A novel derivative of xanomeline improves fear cognition in aged mice.
Si W; Zhang X; Niu Y; Yu H; Lei X; Chen H; Cao X
Neurosci Lett; 2010 Apr; 473(2):115-9. PubMed ID: 20178835
[TBL] [Abstract][Full Text] [Related]
27. Xanomeline suppresses excessive pro-inflammatory cytokine responses through neural signal-mediated pathways and improves survival in lethal inflammation.
Rosas-Ballina M; Valdés-Ferrer SI; Dancho ME; Ochani M; Katz D; Cheng KF; Olofsson PS; Chavan SS; Al-Abed Y; Tracey KJ; Pavlov VA
Brain Behav Immun; 2015 Feb; 44():19-27. PubMed ID: 25063706
[TBL] [Abstract][Full Text] [Related]
28. Differences in kinetics of xanomeline binding and selectivity of activation of G proteins at M(1) and M(2) muscarinic acetylcholine receptors.
Jakubík J; El-Fakahany EE; Dolezal V
Mol Pharmacol; 2006 Aug; 70(2):656-66. PubMed ID: 16675658
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological characterization of M1 muscarinic acetylcholine receptor-mediated Gq activation in rat cerebral cortical and hippocampal membranes.
Odagaki Y; Kinoshita M; Toyoshima R
Naunyn Schmiedebergs Arch Pharmacol; 2013 Nov; 386(11):937-47. PubMed ID: 23748234
[TBL] [Abstract][Full Text] [Related]
30. The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys.
Andersen MB; Fink-Jensen A; Peacock L; Gerlach J; Bymaster F; Lundbaek JA; Werge T
Neuropsychopharmacology; 2003 Jun; 28(6):1168-75. PubMed ID: 12700711
[TBL] [Abstract][Full Text] [Related]
31. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.
Mirza NR; Peters D; Sparks RG
CNS Drug Rev; 2003; 9(2):159-86. PubMed ID: 12847557
[TBL] [Abstract][Full Text] [Related]
32. Wash-resistantly bound xanomeline inhibits acetylcholine release by persistent activation of presynaptic M(2) and M(4) muscarinic receptors in rat brain.
Machová E; Jakubík J; El-Fakahany EE; Dolezal V
J Pharmacol Exp Ther; 2007 Jul; 322(1):316-23. PubMed ID: 17446301
[TBL] [Abstract][Full Text] [Related]
33. On the unique binding and activating properties of xanomeline at the M1 muscarinic acetylcholine receptor.
Christopoulos A; Pierce TL; Sorman JL; El-Fakahany EE
Mol Pharmacol; 1998 Jun; 53(6):1120-30. PubMed ID: 9614217
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of basal and amphetamine-stimulated extracellular signal-regulated kinase (ERK) phosphorylation in the rat forebrain by muscarinic acetylcholine M4 receptors.
He N; Mao LM; Sturich AW; Jin DZ; Wang JQ
Brain Res; 2018 Jun; 1688():103-112. PubMed ID: 29577888
[TBL] [Abstract][Full Text] [Related]
35. Persistent binding and functional antagonism by xanomeline at the muscarinic M5 receptor.
Grant MK; El-Fakahany EE
J Pharmacol Exp Ther; 2005 Oct; 315(1):313-9. PubMed ID: 16002459
[TBL] [Abstract][Full Text] [Related]
36. Involvement of Striatal Cholinergic Interneurons and M1 and M4 Muscarinic Receptors in Motor Symptoms of Parkinson's Disease.
Ztaou S; Maurice N; Camon J; Guiraudie-Capraz G; Kerkerian-Le Goff L; Beurrier C; Liberge M; Amalric M
J Neurosci; 2016 Aug; 36(35):9161-72. PubMed ID: 27581457
[TBL] [Abstract][Full Text] [Related]
37. Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors.
Watson J; Brough S; Coldwell MC; Gager T; Ho M; Hunter AJ; Jerman J; Middlemiss DN; Riley GJ; Brown AM
Br J Pharmacol; 1998 Dec; 125(7):1413-20. PubMed ID: 9884068
[TBL] [Abstract][Full Text] [Related]
38. Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic.
Yohn SE; Weiden PJ; Felder CC; Stahl SM
Trends Pharmacol Sci; 2022 Dec; 43(12):1098-1112. PubMed ID: 36273943
[TBL] [Abstract][Full Text] [Related]
39. Importance and prospects for design of selective muscarinic agonists.
Jakubík J; Michal P; Machová E; Dolezal V
Physiol Res; 2008; 57 Suppl 3():S39-S47. PubMed ID: 18481916
[TBL] [Abstract][Full Text] [Related]
40. Classical and atypical agonists activate M1 muscarinic acetylcholine receptors through common mechanisms.
Randáková A; Dolejší E; Rudajev V; Zimčík P; Doležal V; El-Fakahany EE; Jakubík J
Pharmacol Res; 2015 Jul; 97():27-39. PubMed ID: 25882246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]